Please note: The information displayed on this page might be outdated.
Angiocrine Bioscience: (Private) Developing technologies out of Weill Cornell focused on regeneration of lungs, tendons, cartilage, and liver as well as discovery programs for other tissue types. IND enabling/pre-clinical stage with existing data (some published in Nature and Cell). First generation programs are autologous genetically-modified products, designed for fast entry into clinic and commercialization with a proprietary manufacturing system. Second generation is allogeneic, ‘off-the-shelf’ and potentially universal regenerative products. Also possess an enabling technology for gene-therapy/gene-editing companies.
US - Middle Atlantic
Cell Therapy, Gene Therapy
New York, NY
Company Participants at Solebury Trout KOL Day
- Paul Finnegan, CEO